Cipla rose 2.92% to Rs 422.70 at 9:23 IST on BSE after consolidated net profit rose 10.28% to Rs 485.35 crore on 26.01% increase in total income from operations to Rs 2487.70 crore in Q1 June 2013 over Q1 June 2012.
The result was announced on Friday, 9 August 2013.
Meanwhile, the S&P BSE Sensex was up 115.72 points, or 0.62%, to 18,905.06.
On BSE, 43,000 shares were traded in the counter as against an average daily volume of 1.47 lakh shares in the past one quarter.
The stock hit a high of Rs 426.95 and a low of Rs 420 so far during the day. The stock had hit a 52-week high of Rs 435 on 9 January 2013. The stock had hit a 52-week low of Rs 346.35 on 10 August 2012.
The stock had outperformed the market over the past one month till 8 August 2013, rising 3.56% compared with the Sensex's 2.77% fall. The scrip had also outperformed the market in past one quarter, gaining 1.15% as against Sensex's 6.01% fall.
More From This Section
The large-cap company has an equity capital of Rs 160.58 crore. Face value per share is Rs 2.
On a standalone basis, Cipla's net profit rose 18.5% to Rs 475 crore on 25.3% increase in gross revenues to Rs 2492 crore in Q1 June 2013 over Q1 June 2012. Operating margins grew by 24.8% to Rs 675 crore during the period under review.
The company's material cost was at 40.8% of total sales in Q1 June 2013 as compared to 37.6% in Q1 June 2012.
The company's domestic revenues grew by 16.7% to Rs 1132 crore in Q1 June 2013 over Q1 June 2012. The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics/infectives, and cardiovascular therapy segments.
Exports of formulations grew by 27.7% to Rs 1034 crore in Q1 June 2013 over Q1 June 2012. Exports of Active Pharmaceutical Ingredients (APIs) fell by 13.1% to Rs 146 crore in the same period. The growth in export revenues was primarily due to growth in anti-retroviral, anti-asthma and anti-allergic segments, the company said.
Cipla is a pharmaceutical company. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies. With a turnover of over $1.5 billion, Cipla serves doctors and patients in over 170 countries.
Powered by Capital Market - Live News